Joe Patel currently leads the Biochemistry, Biophysics & Crystallography group at C4 Therapeutics that is tasked with enabling the detailed in vitro and structural characterisation of degraders. Prior to this he spent 6 years as a protein crystallographer and fragment chemistry team leader within the Structure & Biophysics group at AstraZeneca, where he continued to champion the use of FBLG across therapeutic areas and particularly the utility of X-ray cocktail screening to characterize ligand binding pockets. Joe received his Ph.D. in 2001 from the University of Cambridge under the supervision of Prof. Sir Tom Blundell and began his research career at Astex Pharmaceuticals, where he contributed to multiple programs that are currently in late stage clinical studies.